Phase II study of a new regimen for S-1　therapy aiming at adverse reaction mitigation for metastatic gastric　cancer: a study by the Osaka Gastrointestinal Chemotherapy Study Group　OGSG-0103

Phase II study of paclitaxel and doxifluridine in patients with S-1 failure gastric cancer

進行・再発大腸癌に対するUFT/LV+CPT-11併用化学療法の第I相試験(OGSG0303)

遠隔転移を伴う食道癌に対するドセタキセル+シスプラチン+5-FU併用療法の第II相試（OGSG0403）

TS-1 治療抵抗性の進行・再発胃がんに対するpaclitaxel/ doxifluridine 併用療法の第Ⅱ相臨床試験（OGSG 0302）

TS-1 抵抗性進行・再発胃癌に対するPaclitaxel/Doxifluridine併用療法の第Ⅱ相試験（OGSG0302・中間解析）

TS-1 治療抵抗性の進行・再発胃癌に対するPaclitaxel/Doxifluridine 併用療法の第 II 相臨床試験（OGSG 0302）

Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (OGSG 0002)

Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer

Phase I/II multicenter trial of S-1 plus paclitaxel in patients with metastatic gastric cancer: Osaka Gastrointestinal Cancer Chemotheraoy Study Group Study (OGSG 0105)